CTLT vs. ALNY, TEVA, GMAB, RPRX, BGNE, BMRN, VTRS, UTHR, RDY, and SRPT
Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Catalent (NYSE:CTLT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
Alnylam Pharmaceuticals presently has a consensus price target of $216.19, indicating a potential upside of 45.65%. Catalent has a consensus price target of $53.14, indicating a potential downside of 1.22%. Given Catalent's stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Catalent.
Alnylam Pharmaceuticals has a net margin of -16.58% compared to Alnylam Pharmaceuticals' net margin of -26.61%. Catalent's return on equity of 0.00% beat Alnylam Pharmaceuticals' return on equity.
Alnylam Pharmaceuticals received 450 more outperform votes than Catalent when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 59.15% of users gave Catalent an outperform vote.
Catalent has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Alnylam Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.
In the previous week, Alnylam Pharmaceuticals and Alnylam Pharmaceuticals both had 9 articles in the media. Catalent's average media sentiment score of 0.74 beat Alnylam Pharmaceuticals' score of 0.71 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.
Summary
Alnylam Pharmaceuticals beats Catalent on 12 of the 17 factors compared between the two stocks.
Get Catalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalent Competitors List
Related Companies and Tools
